<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144106">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01224730</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol 147</org_study_id>
    <nct_id>NCT01224730</nct_id>
  </id_info>
  <brief_title>A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies</brief_title>
  <official_title>A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AEterna Zentaris</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AEterna Zentaris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I study which will analyze any food-drug effects as well as QTc effects of
      perifosine. Safety and efficacy will also be evaluated.

      Patients who complete the first 24 days on single agent perifosine may have the opportunity
      to 1) continue on single agent perifosine; 2) switch to the combination of capecitabine +
      perifosine; or 3) switch to the combination of sorafenib + perifosine.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effects of food on the PK profile and bioavailability of perifosine, and to evaluate the effects of perifosine treatment on ECG parameters</measure>
    <time_frame>24 days</time_frame>
    <description>To assess the Pharmacokinetic profile of perifosine when given to patients under fed and fasted conditions
To evaluate changes in other ECG parameters associated with perifosine treatment (ventricular rate, PR interval, QRS interval, QT interval)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and efficacy of perifosine when given to patients with advanced malignancies</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>To evaluate the safety profile (adverse events) and efficacy (response rate, and time to progression) of all study patients treated with perifosine.
After Day 24, to evaluate the safety profile (adverse events) and efficacy (response rate and time to progression) of all study patients who remain on single agent perifosine, switch to the combination of capecitabine + perifosine or switch to the combination of sorafenib + perifosine.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Perifosine 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perifosine 100 mg orally daily under Fed and Fasted conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>perifosine</intervention_name>
    <description>100 mg daily</description>
    <arm_group_label>Perifosine 100 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with advanced malignancies

          -  Patients with adequate organ and marrow function

        Exclusion Criteria:

          -  Patients previously treated with perifosine

          -  Patients receiving any other chemotherapy, targeted agents, investigational agents or
             devices within four weeks (28 days) prior to Day 1 of study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ed Cullen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Keryx / AOI Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>May 2012</verification_date>
  <lastchanged_date>May 30, 2012</lastchanged_date>
  <firstreceived_date>October 19, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
